Introduction
============

Renal Clear Cell Carcinoma (RCC) comprises \>80% of renal malignancies in adults ([@b1-ol-0-0-5822]). Common sites of RCC metastasis include the lung, bone, liver and adrenal glands ([@b2-ol-0-0-5822]). The thyroid gland, however, represents a less common metastatic target site for renal malignancies in general, and RCC in particular ([@b2-ol-0-0-5822]). The incidence of metastasis to the thyroid was revealed to occur in 1.25--24% of autopsy cases ([@b2-ol-0-0-5822]). According to the US National Cancer Institute (Rockville, MD, USA), the five-year survival rate for patients diagnosed with renal cancer is \~73.2%, and this number decreases to \~11% with proven metastasis ([@b3-ol-0-0-5822]).

There have been several reports in the literature of acquired arteriovenous malformations (AVM) being mistaken for RCC ([@b4-ol-0-0-5822]). Conversely, RCCs have also been mistaken for AVMs ([@b5-ol-0-0-5822]). Radiologically, an AVM may take numerous forms, with masses ranging from cystic to solid necrotic, from homogeneous to heterogeneous and from small to large ([@b6-ol-0-0-5822]). To the best of our knowledge, an AVM associated with RCC metastasis to the brain has never been reported in the literature. The typical clinical presentation of an AVM includes the cardinal features of hemorrhage, seizures, progressive neurological deficits or headache ([@b7-ol-0-0-5822]). However, recent animal models have postulated that genetic manipulation and angiogenic stimulation, including malignancy, are required for AVM development and are independent of congenital etiologies ([@b8-ol-0-0-5822]). The current study presents a case of RCC metastasis to the thyroid gland, with an AVM associated with metastatic involvement in the brain. This case is unique as the metastasis to the thyroid was only detected due to the clinical manifestations of a cerebral AVM.

Case investigations, research and writing were conducted at the Miami Valley Hospital in Dayton Ohio, a teaching institution for Wright State University Boonshoft School of Medicine. The case presented is unique in that it informs the academic community of a novel presentation of renal cell carcinoma that has metastasized to the thyroid and brain. Furthermore, it demonstrates how a presentation of what appears to be an AVM is anything but. Lastly, the metastasis of RCC to the thyroid is a rare event that was further unusual in this case in that it was detected only by diagnosis of the 'AVM'.

Case report
===========

A 45-year-old African-American female presented to the Miami Valley Hospital Emergency Department (Dayton, OH, USA) in November 2015 with left-sided weakness, slurred speech, facial droop and a grand-mal seizure. The patient\'s medical history was notable for a diagnosis of RCC, 2010 American Joint Committee on Cancer Tumor-Node-Metastasis Stage 1B (T1B, N0, M0) grade III status post-right robotic-assisted partial nephrectomy 18 months prior. There was no personal or family history of seizure disorders or neurologic diseases. A review of subjective symptoms was negative for vision changes, fevers, chills, weight changes, unilateral weakness, or decreased sensation. Physical examination revealed an unresponsive patient with spontaneous movement of the right side, but flaccid paralysis of the left upper and lower extremities. No thyromegaly, thyroid nodules, cervical or submandibular lymph nodes were palpated. Laboratory tests revealed that blood, liver and kidney function were normal. Magnetic resonance imaging (MRI) of the cervical, thoracic and lumbar spine revealed signs of a metastatic lesion. The patient had numerous episodes of focal status epileptics during hospitalization. After several days, the patient underwent a right partial parietal craniotomy with resection of the intra-axial mass; subsequent pathology was inconclusive for a malignancy and consistent with an AVM.

Due to the thyroid mass observed on the MRI, a positron emission tomography (PET)/computed tomography (CT) scan was performed, which revealed a hypermetabolic area in the left lobe of the thyroid extending into the left aspect of the isthmus. A corresponding ultrasound of the thyroid identified a homogeneous hypervascular lesion throughout the left lobe that extended into the isthmus and had poorly-defined borders. Fine needle aspiration of the thyroid and subsequent histopathological analysis revealed the thyroid tumor to be comprised of clear cell carcinoma cells. Immunohistochemical analysis ([Figs. 1](#f1-ol-0-0-5822){ref-type="fig"}--[4](#f4-ol-0-0-5822){ref-type="fig"}) of 10% formalin-fixed paraffin-embedded aspirate tissue sections (4-µm thick) of the thyroid tumor revealed the following: Polyclonal cytokeratins 1/3 (AE1/3; 1:450 dilution; catalog no. M3515; Agilent Technologies, Inc., Santa Clara, CA, USA), positive; vimentin, positive; paired box gene 8 (PAX8; 1:400 dilution; catalog no. 363M-16; Cell Marque, Rocklin, CA, USA), positive; renal cell carcinoma (PN-15; 1:300 dilution; catalog no. 329M-97; Cell Marque), positive; cluster of differentiation (CD) 10 (1:10 dilution; catalog no. AC-0169; Epitomics, Burlingame, CA, USA), positive; cytokeratin 20 (CK20), negative; cytokeratin 7 (CK7), negative; thyroglobulin, negative; and thyroid transcription factor-1, negative. Detection was carried out using DAKO EnVision™ Flex+ and DAKO Austostainer Link (Dako; Agilent Technologies, Inc.). All antibody details are illustrated in [Table I](#tI-ol-0-0-5822){ref-type="table"}. Metastatic involvement of the thyroid was determined to be associated with the patient\'s prior history of grade III RCC. In addition to being referred to radiation-oncology and neurology-oncology surgery, the patient was placed on Keppra, remained seizure free and was started on pazopanib as an outpatient.

Several months after discharge, the patient was readmitted to the Miami Valley Hospital for worsening headaches, nausea and vomiting. CT and MRI scans of the brain revealed the recurrence of a 1.9 cm mass in the right parietal lobe with extensive vasogenic edema ([Fig. 5](#f5-ol-0-0-5822){ref-type="fig"}). Biopsy of the mass at several distinct points indicated a vascular lesion composed of numerous vessels of varying caliper, suggestive of AVM. Immunostaining revealed the mass to be AE1/3, cytokeratin (MNF116; 1:150 dilution; catalog no. M0821; Agilent Technologies), PAX8 and PN-15 negative. The patient was readmitted again to the hospital after several months for worsening headaches, nausea and vomiting. CT and MRI scans of the brain revealed the return of a 3.7 cm mass exhibiting vasogenic edema. Biopsy of this novel mass did not suggest an AVM, rather the immunohistochemical stains demonstrated the following: Glial fibrillary acidic protein, negative; vimentin, CD10, PN-15, PAX-8 and cytokeratin AE1/3, positive; CK7 and CK20, negative. The findings from the novel lesion supported a diagnosis of metastatic RCC. [Fig. 6](#f6-ol-0-0-5822){ref-type="fig"} presents PET imaging, which suggested metastasis to the thyroid.

Discussion
==========

RCC accounts for \<5% of all malignant tumors ([@b9-ol-0-0-5822]). Metastasis is common in patients with RCC, with typical sites including the lungs, lymph nodes, bone, and liver ([@b10-ol-0-0-5822]). Metastasis to the head and neck region is less common ([@b11-ol-0-0-5822]). To the best of our knowledge, RCC metastasis to the brain associated with AVM formation has not been reported in the literature to date. More commonly, AVMs associated with RCC are located in the renal vasculature and present with the cardinal symptom of flank pain ([@b5-ol-0-0-5822]). Recent literature has commented on the association between AVMs and RCC as they share highly vascular characteristics ([@b5-ol-0-0-5822]). It was previously considered that various types of cancer have high circulating expression levels of plasma vascular endothelial growth factor (VEGF) ([@b12-ol-0-0-5822]). However, a recent study demonstrated that free VEGF plasma levels are low or absent in numerous types of cancer, with the exception of RCC ([@b13-ol-0-0-5822]). RCC is a vascular tumor that has been demonstrated to lead to the abnormal expression of various angiogenesis-promoting growth factors ([@b14-ol-0-0-5822]). VEGF is the central pro-angiogenic agent involved in RCC carcinogenesis, and is associated with mutations in the von Hippel-Lindau tumor suppressor (*VHL*) gene ([@b14-ol-0-0-5822]). Somatic *VHL* mutations have been associated with persistently high expression levels of hypoxia-inducible factor-1α signaling pathway proteins, and with VEGF expression in patients with metastatic RCC ([@b15-ol-0-0-5822]).

Recent studies using animal models have postulated that genetic manipulation and angiogenic stimulation are each required for AVM development, and are independent of congenital etiologies ([@b8-ol-0-0-5822]). It may be theorized that the dysregulation of pro-angiogenic factors associated with RCC development contributes to the development of AVMs observed in this type of malignancy. These angiogenic factors are vital to the pathophysiological pathway that leads to RCC, and may well explain the development of AVMs within these neoplasms as demonstrated in the aforementioned case. DNA sequencing of AVM tissue from a patient with Proteus-like syndrome has revealed *PTEN* mutations that have been previously implicated in Cowden\'s syndrome ([@b16-ol-0-0-5822]). With the use of immunohistochemical staining on tissue samples from similar areas of the brain, the progression of negative markers for malignancy in the setting of an AVM to positive markers for malignancy in the absence of AVM was demonstrated. It has been noted that certain pathologists have stated that an AVM and RCC may be regarded as associated entities, rather than distinct processes, in the context of surgical histopathology. Conversely, the case has been presented for serial MR imaging of supposed AVMs in order to distinguish them from malignancies, specifically RCC ([@b5-ol-0-0-5822]).

The patient in the current case was further unusual in that they developed biopsy-confirmed renal metastasis to the thyroid. Typically, patients with RCC metastasis to the thyroid are detected following a physical exam, not in the setting of a coinciding metastasis to the brain ([@b17-ol-0-0-5822]). Metastases to the thyroid have generally been revealed to occur several years following nephrectomy ([@b10-ol-0-0-5822]). It is unclear why metastasis to the thyroid is a rare event, as it has a rich vascular supply ([@b18-ol-0-0-5822]).

Current guidelines pertaining to metastatic RCC do not recommend routine brain imaging for surveillance purposes unless there are concurrent CNS symptoms or other abnormalities indicating brain involvement ([@b19-ol-0-0-5822]). Patients with a history of tobacco abuse and pulmonary metastases are more likely to have metastasis to the brain; therefore, this may serve as an indication for surveillance imaging of the brain ([@b19-ol-0-0-5822]). With increasing understanding of the role of angiogenic dysregulation in the pathogenesis of RCC, novel therapeutic strategies are utilizing targeted anti-angiogenic agents with varying degrees of success ([@b20-ol-0-0-5822]).

In conclusion, brain metastasis must be considered in patients with a positive history of RCC, who present with an acute onset neurological event and apparent AVM on initial biopsy. Postoperative distinction between AVM and metastasis to the brain may be difficult to distinguish, as discussed in the aforementioned case. A high index of suspicion for brain metastasis, despite initial negative immunohistochemical testing, should be followed up by a repeat biopsy of the tissue in question at a later date. This may assist in guiding palliative therapy should the otherwise prognostically favorable AVM be determined to be a prognostically unfavorable metastasis to the brain.

![Pathological examination of the thyroid gland resected during surgery. Polyclonal cytokeratins 1/3+ staining (magnification, ×200).](ol-13-05-3323-g00){#f1-ol-0-0-5822}

![Pathological examination of the thyroid gland resected during surgery. Cluster of differentiation 10 immunohistochemical staining (magnification, ×200).](ol-13-05-3323-g01){#f2-ol-0-0-5822}

![Pathological examination of the thyroid gland resected during surgery. Hematoxylin and eosin staining (magnification, ×400).](ol-13-05-3323-g02){#f3-ol-0-0-5822}

![Pathological examination of the thyroid gland resected during surgery. PAX-8 staining (magnification, ×200).](ol-13-05-3323-g03){#f4-ol-0-0-5822}

![Magnetic resonance imaging of the brain with contrast depicting a right posterior mass with vasogenic edema.](ol-13-05-3323-g04){#f5-ol-0-0-5822}

![Monochrome positron emission tomography performed during initial evaluation of suspected renal clear cell carcinoma metastasis.](ol-13-05-3323-g05){#f6-ol-0-0-5822}

###### 

Antibodies utilized in immunohistochemical staining for renal cell carcinoma.

  Immunohistochemistry antibody     Clone         Dilution    Manufacturer                                               Cat. no.
  --------------------------------- ------------- ----------- ---------------------------------------------------------- ----------
  AE1/AE3                           AE1 & AE3     1:450       Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          M3515
  CD10                              EP195         1:10        Epitomics^[b](#tfn2-ol-0-0-5822){ref-type="table-fn"}^     AC-0169
  PAX8                              MRQ-50        1:400       Cell Marque^[c](#tfn3-ol-0-0-5822){ref-type="table-fn"}^   363M-16
  PN15                              PN-15         1:300       Cell Marque^[c](#tfn3-ol-0-0-5822){ref-type="table-fn"}^   329M-97
  Vimentin                          V9            1:125       Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          M072529
  Cytokeratin 20                    Ks20.8        1:300       Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          M701901
  Cytokeratin 7                     OV-TL 12/30   1:500       Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          M701801
  Thyroglobulin                     Polyclonal    1:100,000   Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          A025102
  Thyroid transcription factor      8G7G3/1       1:400       Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          M357501
  Glial fibrillary acidic protein   Polyclonal    1:12,000    Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          Z033401
  MNF116 cytokeratin                MNF116        1:150       Dako^[a](#tfn1-ol-0-0-5822){ref-type="table-fn"}^          M0821

Agilent technologies Inc., Santa Clara, CA, USA

Burlingame, CA, USA

Rocklin, CA, USA. AE1/3, cytokeratin 1/3; CD, cluster of differentiation; PAX8, paired box gene 8; PN-15, renal cell carcinoma.
